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Abstract
Objective: To examine the optimal duration of antibiotic prophylaxis in major cardiovascular surgery. Methods: In the past 15 years, four
prospective randomized, controlled studies, conducted by the same group of authors, compared seven prophylactic antimicrobial regimens in
2970 patients undergoing major cardiovascular surgery. In 1980/81, a 4-day cefazolin (CFZ) prophylaxis was compared with a 2-day
cefuroxime (CFX) administration (n  566). In 1982/83, a 2-day CFX prophylaxis was compared with a two shot ceftriaxone (CRO)
prophylaxis (n  512). In 1984/87, a 1-day CFZ prophylaxis was compared with a single shot prophylaxis of CRO (n  883). In 1994/
1995, a 4 day combination of amoxicillin (AM) and netilmicin (NET) prophylaxis was compared with a single shot prophylaxis of CFX
(n  1009). Results: Total infection rate varied between 4.5 and 5.7%, despite different antimicrobial regimen used and their varying
duration. Wound infection rate was 1.1% (range 0.4±2.5%), sepsis rate was 0.8% (range 0.4±1.6%), pneumonia rate 2% (0.7±2.9%), urinary
tract infection rate 0.4% (range 0±1.4%), and central venous catheter-related infection rate was 0.4% (0±1%). The 30-day mortality rate was
1.3% (range 0.4±2%). All these differences were not statistically signi®cant. Conclusions: A low infection rate (range 4.5±5.7%) occurred
despite changes in duration of various prophylactic antibiotic regimen with cephalosporins of ®rst, second or third generation. As a single
shot prophylaxis could nowadays successfully be used in cardiovascular surgery, no postoperative antibiotics should be used, unless an
intraoperative or a postoperative infection is documented or in presence of major perioperative complications. q 2000 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Prophylactic antibiotics have been used in cardiovascular
surgery for several years, in order to reduce the risk of post-
operative infections [1,2]. The initial long duration of anti-
microbial administration was progressively shortened. In
the late 1970s, duration of the antimicrobial regimen
given as prophylaxis (cefazolin 4 £ 0.5 g/day, i.v.) has
decreased from 7 to 4 days safely. In the following years,
seven different antimicrobial regimen with different dura-
tion, progressively shorter, (4 days vs. 2 days, 2 days vs. 2
doses, 1 day vs. 1 dose, 4 days vs. 1 dose) were compared in
prospective randomized trials by one of the authors (S.G.).
Aim of this study was `meta-analysis' of four consecutive
trials dealing with antibiotic prophylaxis in cardiovascular
surgery. Main goal of this study was to evaluate the effect of
reduction of antibiotic prophylaxis in postoperative infec-
tious complications.
2. Patients and methods
Between 1980 and 1995, four randomized studies
compared seven different perioperative prophylactic antimi-
crobial regimen in major cardiovascular surgery. The ®rst
three studies were performed at the University Hospital of
Zurich, the last one at the Onassis Cardiac Surgery Center,
in Athens. The procedures followed were in accordance
with the Helsinki declaration.
Between September 1980 and July 1981, a 4-day cefazolin
(CFZ) prophylaxis (4 £ 0.5 g/day, i.v.) was compared with a 2-
day cefuroxime (CFX) administration (2 £ 1.5 g/d, i.v.). Of
569 patients who entered the study, 281 received CFZ and 285
CFX [3]. Between May 1982 and March 1983, a 2-day CFX
prophylaxis (4 £ 1.5 g/day, i.v.) was compared with a two shot
ceftriaxone (CRO) prophylaxis (2 g plus 1 g 24 h later, i.v.). Of
523 patients enrolled, 258 received CFX and 254 CRO [4].
Between November 1984 and March 1987, a 1-day CFZ
prophylaxis (4 £ 0.5 g, i.v.) was compared with a single shot
prophylaxis of CRO (1 £ 2 g, i.v.). Of 883 patients enrolled,
439 received CFZ and 444 CRO [5]. Between May 1994 and
April 1995, a 4-day amoxicillin (AM) plus netilmicin (NET)
prophylaxis (3 £ 2 g 1 2 £ 150 mg/day, i.v.) was compared
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with a single shot prophylaxis of CFX (1 £ 3 g, i.v.). Of 1009
patients enrolled, 508 received AM-NET and 501 CFX [6].
All patients aged over 16 years undergoing open heart
surgery or major vascular surgery were eligible for trial
entry (except the fourth study where no major vascular
surgery was included except thoracic aorta aneurysms).
All patients with preoperative infection, those who had
received any antibiotic within 48 h prior to operation and
those with known allergy to b-lactamic antibiotics were
excluded from the study protocol.
Patients were allocated to one of two treatment groups by
means of a randomized code, strati®ed for cardiac and major
vascular operations. The ®rst dose was always given prior to
surgery, just prior the induction of anesthesia. Treatment
groups were well matched for age, sex, weight, height and
type of surgical procedure in all studies. There were no statis-
tically signi®cant differences in co-morbid conditions, such
as history of diabetes mellitus and/or renal failure and/or
chronic obstructive pulmonary disease (COPD), obesity,
and prolonged preoperative hospitalization between groups
among these four trials included. In addition, there were no
differences between groups regards to bleeding requiring re-
exploration. In these studies, there were no patients who
underwent coronary artery bypass grafting with bilateral
mammary artery. In all patients who received a single shot
of antibiotic prophylaxis, regimen was administered just
prior the induction of anesthesia. In this case, no additional
dosage was administered in the pump priming solution, as
well as in patients with a prolonged duration of extracorpor-
eal circulation.
Hematological tests, liver function tests, serum creatinine
and urea were measured preoperatively. These measure-
ments were repeated daily during the ICU period, one
week after and/or immediately before discharge. Chest X-
rays were taken before, immediately after the operation, 1
and/or 2 days later prior to leaving hospital and in between
when clinically indicated. Body temperature was measured
every 1 or 2 h during the ICU period and in the ward at least
twice daily. Surgical wounds were examined daily and
swabs of any secretions or pus were taken for bacteriologi-
cal examinations. Central venous catheters remained in the
majority of patients one day. In patients with prolonged ICU
length of stay, all central catheters changed in case of suspi-
cion of central venous catheter-associated infection or
sepsis. Swan±Ganz catheters were removed prior to the
fourth postoperative day. Postoperative infections were
treated with appropriate antibiotics and when needed, surgi-
cal intervention.
2.1. De®nitions
Wound infection was de®ned as purulent secretion with
growth of bacteria, classi®ed into mild (purulent discharge
only), moderate (discharge of pus plus constitutional upset)
and severe (requiring active surgical intervention such as
reoperation) [7]. Urinary tract infection was de®ned as clin-
ical signs of infection in combination with urine cultures
demonstrated a pathogen numbering .100 000 c.f.u. ml21
[8].
The diagnosis of pneumonia in the ®rst three studies was
made when three of the following criteria were present:
purulent sputum, rales, fever, and positive chest X-ray. In
the last study, two more criteria were added: leukocytosis,
and positive culture. Diagnosis was made when four out of
six criteria were present [9].
The patients were de®ned as having sepsis if they mani-
fested the following: (1) at least two of the following
criteria: (a) body temperature .388C, (b) WBC counts
.12 £ 109/l or ,4 £ 109/l or immature neutrophils .10%,
(c) heart rate .90 beats/min, and (d) respiratory rate .20
breaths/min or PaCO2 ,32 mm Hg; (2) a documented
bacteremia [10].
Chest X-rays, blood cultures and urine sedimentation
tests were negative in patients with fever (.398C) of
unknown origin.
2.2. Demographic data
The randomization in each study produced groups with
well-matched demographic data (Table 1).
2.3. Surgical procedures
A total of 3122 patients entered the four studies. Of these,
152 were excluded for various reasons. Out of 2970 patients
examined, 2708 underwent open heart surgery and 262
major vascular surgery (Table 1). The majority of opera-
tions were aortocoronary artery bypass grafting (n  1822,
61.3%) with an increased trend during this period, followed
by valve replacement (n  739, 24.9%), associated with a
decreased trend. Surgery of major arteries with implantation
of a vascular prosthesis accounted for 262 (8.8%) opera-
tions. The remaining 147 (4.9%) were other operations
with use of cardiopulmonary bypass (PCB). In all studies,
both groups were well matched for the type of operation
(Table 1).
2.4. Statistical analysis
Values are presented as mean ^ SD or numbers and
percentile. A P-value less than 0.05 was considered statis-
tically signi®cant.
3. Results
3.1. Infection rate
Wound infection developed in 33 patients (1.1%, range
0.4±2.5%). There were 17 severe sternal wound infections
that required reoperation, six moderate sternal wound infec-
tions, three moderate inguinal wound infections and seven
mild or moderate donor site wound infection (Table 2).
Patients with sternal wound infections had prolonged opera-
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tion times (.120 min.) and major perioperative complica-
tions or they were re-explorated because of bleeding.
Sepsis developed in 24 patients (0.8%, range 0.4±1.6%).
Pneumonia developed in 61 patients (2%, range 0.7±2.9%).
Urinary tract infections occurred in 11 patients (0.4%, range
0±1.4%). Central venous catheter-related infection devel-
oped in 13 patients (0.4%, range 0±1%). Fever of unknown
origin occurred in 87 patients (2.9%).
Total postoperative infection rate was 5.2% (range 4.5±
5.7%) (Table 2). There were no statistically signi®cant
differences regards to kind of infection between various
regimen. Infection rate did not vary signi®cantly during
this period, while the duration of the regimen became
progressively shorter.
Isolated pathogens for all studies are shown in Table 3.
There was no statistically signi®cant difference between the
various regimen in the occurrence of Gram positive cocci
and Gram negative rods. In contrast, there was a difference
in the occurrence of Gram positive cocci and Gram negative
rods regarding the type of infection. Pathogens isolated
from infected wounds were mainly Gram positive cocci
while those isolated from other infections like pneumonia
or urinary tract infections were Gram negative rods.
3.2. Biochemical measurements
There were no signi®cant differences in the pre-treatment
or follow-up biochemical measurements. All minor changes
observed were not clinically signi®cant and they were not
related to administered antibiotics. There were no side
effects reported in these studies, except two cases of diar-
rhea due to Clostridium dif®cile. Being overt infections in
the postoperative period, they were classi®ed as infections
and not as side effects.
3.3. Hospital stay
During this period, a light decrease of hospital length of
stay was observed from 10.5 to 9.3 days (Table 2).
3.4. Mortality
A total of 38 patients (1.3%) died within a month. For 25
patients, main cause of death was cardiogenic shock, for
seven patients cause of death was multiple organ failure,
while in six patients (0.2%), death was exclusively due to
a severe infection. Of these six patients, nosocomial pneu-
monia was the main cause of death in three patients and
sepsis in the remaining three ones.
4. Discussion
Postoperative infection following cardiovascular surgery
is a serious and often life-threatening complication [11,12].
It is associated with a substantial morbidity, prolonged
hospital stay and an increasing hospital cost.
Prophylactic antibiotics have been used for several years
in order to reduce the risk of postoperative infections [1,2].
Cephalosporins are frequently used because of their broad
spectrum of activity and low degree of toxicity [13].
However, the number of resistant microorganisms is
increasing, particularly the b-lactamase producing gram-
negative organisms capable of destroying many penicillins
and cephalosporins [14].
The reason for the development of resistant strains is prob-
ably the long-term application of antibiotics. The shortest
effective treatment will be therefore of advantage [15]. An
effective prophylactic regimen should be directed against the
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Table 3
Isolated microorganismsa
Microorganism 1980±81 1982±83 1984±87 1994±95 Total
CFZ CFX CFX CRO CFZ CRO CFX A-N
Staphylococcus (coagulase negative) 2 2 2 3 7 13 6 9 44
Staphylococcus aureus 1 4 1 2 8 5 8 6 35
Enterococcus 1 1 2 3 3 1 0 0 11
Enterobacter 2 1 2 2 2 4 3 2 18
Serattia marcescens 3 1 2 2 4 3 1 1 17
E. coli 2 4 3 1 4 0 1 1 16
Streptococci 0 0 0 0 3 1 1 3 8
Pseudomonas 1 2 2 2 0 0 0 2 9
Klebsiella 1 2 2 1 1 0 1 1 9
Haemophilus 0 1 0 0 4 1 0 0 6
Proteus 1 2 0 0 2 0 0 0 5
Acinetobacter 0 1 0 0 1 0 0 0 2
Citrobacter 0 0 0 1 0 0 0 0 1
Candida 0 1 1 0 0 0 0 1 3
Bacillus sp. 0 0 0 0 0 1 0 0 1
Corynebacterium 1 1 1 0 0 0 0 0 3
Morganella morganii 0 0 0 0 0 0 1 0 1
a CFZ, cefazolin; CFX, cefuroxime; CRO, ceftriaxone; A-N amoxicillin 1 netilmicin.
most likely pathogens but need not to include drugs active
against every potential pathogen. Regimens that decrease the
total number of exogenous or endogenous infecting organisms
permit host defenses to resist clinical infection [16]. Clinical
and experimental studies have shown that antibiotics could be
effective only under certain conditions. It is necessary to
achieve high level concentrations in serum and tissues during
the operative procedure, which is the time of maximal contam-
ination [17,18]. When the drug is undetectable during or at the
end of operation, infection is relatively common [19]. There-
fore, the optimal time for administration of prophylaxis is at
the induction of anesthesia [16].
In case of re-exploration, it is recommended to repeat
antibiotic prophylaxis in order to achieve again adequate
plasma levels during the critical period of the surgery proce-
dure, unless a long acting drug is used. All these recommen-
dations have been followed in the above trials. It is doubtful
that postoperative infections can be entirely eliminated.
Apart from the use of antibiotics, other measures must be
taken in order to decrease the risk of infection. Optimizing
the operating room environment, the surgical and operating
room protocols and the awareness of personnel can all
contribute to lowering infection rates [20].
However, the optimum duration of the antibiotic regimen
has been controversial for long time. In the early period of
cardiac surgery, antibiotics were administered for several
days. The shortest safe period remained unclear, especially
in the case of single shot prophylaxis that stayed for a long
period controversial.
5. Historical background
Sutherland et al. published, in 1979, a prospective study
of 693 consecutive patients showing that in elective coron-
ary surgery no antimicrobial prophylaxis was necessary
[21]. The wound infection rate was 0.8%. These results
initiated a worldwide discussion.
At that time, in the Department of Surgery at the Univer-
sity Hospital in Zurich, cefazolin (4 £ 0.5 g, i.v.) was
applied in routine cardiac surgery for 4 days. However,
this treatment was often continued for 7±10 days.
On the occasion of Sutherland's publication we searched
retrospectively 500 consecutive patients and found that the
postoperative infection rate in the 4-day cefazolin group was
6%, while in the 7-day group rate was 12%. It was clear that
such a study had no major value, as high risk patients and
those with complications were treated longer with antimi-
crobials. Nevertheless, it became obvious that a longer anti-
microbial application was not of de®nite advantage.
A prospective randomized study comparing placebo with
4-days of cefazolin administration was considered too risky
and most probably unethical due to the results of Fong et al.
who had shown a very high infection rate in the placebo
group [22]. We therefore designed and performed in 1980/
81 our ®rst prospective randomized study comparing a 4-
day cefazolin (4 £ 0.5 g/day, i.v.) administration with a 2-
day cefuroxime (2 £ 1.5 g/day, i.v.) regimen. In this study,
566 patients were enrolled: 281 in the cefazolin and 285 in
the cefuroxime regimen. Neither in the 30 days total infec-
tion rate (5.7 vs. 5.3%) nor in the wound infection rate (2.5
vs. 1.1%) statistical difference could be observed, although
the trend was in favor of the shorter regimen [3].
In 1982/83, the next study compared the 2-day cefurox-
ime regimen (2 £ 1.5 g, i.v.) with a 2-dose ceftriaxone (2 g
at the induction of anaesthesia plus 1 g 24 h later). Of the
512 patients enrolled in the study, 258 received cefuroxime
and 254 ceftriaxone. Again, no difference in total (4.7%)
and in wound infection rate (1.2%) was found [4].
In the meantime, in order to be sure that a single dose
ceftriaxone application would be suf®cient, we conducted
an extensive pharmacokinetic study measuring plasma
levels in the ®rst 24 h after 2 g ceftriaxone given at the
induction of anesthesia [23]. In this study, 110 patients
were enrolled. The plasma levels were so high (265 mg/ml
at the beginning of the operation, 103 mg/ml at the begin-
ning of the cardiopulmonary bypass, 95 mg/ml at the end of
operation, and 24 mg/ml 24 h later), that the MIC90 of
bacteria like Enterococci (128 mg/ml), Pseudomonas aeru-
ginosa (64 mg/ml) and Bacteroides (32 mg/ml) were lying
under the curve [23].
Therefore, we skipped the above mentioned study and
decided to compare the single dose ceftriaxone regimen to
the universally used and worldwide accepted antimicrobial
prophylaxis regimen with cefazolin (4 £ 0.5 g for 1 day).
Out of 883 patients, 439 received cefazolin and 444
ceftriaxone. Again, no difference in the 30 days total infec-
tion rate (5 vs. 4.5%) and the 30 days wound infection rate
(0.4 vs. 1.3%) was found [5].
In order to be sure that not only the 30 days infection rate
was more or less similar between the two treatment groups
we continued the study up to 1049 patients and checked the
6 months infection rate [24]. The 30 days total infection rate
was 5.1 vs. 5.3% and the 30 days wound infection rate was
0.8 vs. 1.9%. The 6 months total infection rate was 7.6 vs.
9.3%, again not showing any statistically signi®cant differ-
ence between the two groups.
In 1993, one of the authors (S.G.) left the University
Hospital of Zurich to work for the newly formed Onassis
Cardiac Surgery Center, in Athens. Three surgical teams of
the Center (trained in USA) had agreed to administer as
surgical prophylaxis netilmicin (2 £ 150 mg i.v.) and amox-
icillin (3 £ 2 g i.v.) both for 4 days. An ideal situation to
compare a single dose prophylaxis to a 4-day regimen.
There had been already a background of 1000 operations
with the above regimen before starting in 1994 the next
study comparing a single dose cefuroxime vs. a 4-day amox-
icillin/netilmicin regimen. Out of 1009 patients enrolled,
508 received amoxicillin plus netilmicin and 501 cefurox-
ime. Total infection rate (5.6 vs. 5.7%) and wound infection
rate (0.6 vs. 1.2%) were again similar in both groups [6].
In the present study we have put together the results of the
I. Kriaras et al. / European Journal of Cardio-thoracic Surgery 18 (2000) 440±446 445
four major studies which enable the comparison of the various
regimen: 4 vs. 2 days, 2 days vs. 2 doses, 1 day vs. single dose,
and at the end single dose vs. 4 days. The circle is in this way
closed and the results show a unique similarity. Despite the
different duration time of the antibiotic administration and the
different antibiotics used (cephalosporins of the ®rst, second
and third generation, plus a combination of netilmicin and
amoxicillin), the total wound infection rate in our meta-analy-
sis (n  2:970 patients) was 1.1%. Range varied between 0.4
and 2.5% and trend was generally in favor of the shorter regi-
men! Sepsis rate was 0.8% (range 0.4±1.6%); nosocomial
pneumonia rate was 2.0% (range 0.7±2.9%); UTI rate was
0.4% (range 0±1.4%). Total infection rate was 5.2% (range
4.5±5.7%).
All these results were similar despite the change of
patients' mean age from 53 to 60 years, the higher risk
group, and the change of patients' mean weight from 68
to 77 kg.
It is interesting to note that in the ®rst three studies the
comparison was made between consecutive regimen vary-
ing from 4 days to a single dose regimen, but this compar-
ison was not made contemporary. In contrast, in the last
study the comparison of single dose versus the 4-day regi-
men has been made contemporary. In addition, the result of
the latter study was not in¯uenced from changes that had
been made during those years regarding the perioperative
conditions and operating protocols. Total infection rate has
not changed during those years. This fact could mean that
total infection rate could not easily diminish further by using
newer cephalosporins nor by varying the antimicrobial regi-
men. However, things change rapidly in cardiovascular
surgery. For this reason, a continuous re-evaluation of anti-
microbial policy is necessary. Data from different institu-
tions should be taken into consideration for the choice of the
optimum prophylactic antimicrobial regimen. Local resis-
tance problems with MRSA, MRSCN or vancomycin resis-
tant Enterococci may need other more potent regimen.
6. Conclusions
The `meta-analysis' of these four studies, which
compared seven different regimen since 1980, showed no
statistically signi®cant difference in the frequency of post-
operative infectious complications. If a cephalosporin is
administered properly at the induction of anesthesia, a low
infection rate occurs that can not be lowered further by
longer duration of antimicrobial administration. A single
dose prophylaxis of 2 g ceftriaxone (i.v.) or 3 g cefuroxime
(i.v.) is safe, cheep and effective.
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